We are live on ! Find out more
BCM

Biomark Capital Management Portfolio holdings

AUM $8.9M
1-Year Est. Return 97.06%
This Fund
S&P 500
This Quarter Est. Return
+6.42%
1 Year Est. Return
+97.06%
3 Year Est. Return
+113.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$82.2M
AUM Growth
–
Cap. Flow
+$92.5M
Cap. Flow %
112.59%
Top 10 Hldgs %
100%
Holding
3
New
3
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$79.5M
2
ADMA icon
ADMA Biologics
ADMA
+$12.9M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 14.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
$70.5M 85.76%
+1,602,562
New +$79.5M
ADMA icon
2
ADMA Biologics
ADMA
$1.96B
$11.6M 14.08%
+1,433,304
New +$12.9M

Similar funds

OBP
Old Bellows Partners New York $9.01M AUM 83.84% 1-Year Est. Return
HC
Highstar Capital New York $8.59M AUM 3.82% 1-Year Est. Return
SBA
Seven Bridges Advisors New York $9.75M AUM 16.73% 1-Year Est. Return
CIG
Candlewood Investment Group Rye, New York $10.1M AUM 30% 1-Year Est. Return
LRM
Lime Rock Management Westport, Connecticut $7.54M AUM 22.09% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
GA
Glenhill Advisors New York $6.94M AUM 24.62% 1-Year Est. Return
CCM
Catalus Capital Management Greenwich, Connecticut $6.09M AUM 3.76% 1-Year Est. Return

Biomark Capital Management's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for Biomark Capital Management, which disclosed 3 positions worth $82.2M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Juno Therapeutics, Inc.: 1,602,562 shares worth $70.5M.

By sector, the portfolio is most concentrated in Healthcare at 14% of assets.

  • Biomark Capital Management's largest Q4 2015 buy was Juno Therapeutics, Inc.: 1,602,562 shares worth $70.5M.
  • Biomark Capital Management's ten largest holdings make up 100% of its $82.2M portfolio in Q4 2015.
  • Biomark Capital Management disclosed 3 positions in Q4 2015, its first 13F filing on record.

Based on Biomark Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.